Patent application number | Description | Published |
20090312369 | Renin Inhibitors - The present invention is directed to aspartic protease inhibitors represented by the following structural formula (I), or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the aspartic protease inhibitors of Structural Formula (I). Methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using these aspartic protease inhibitors are also disclosed. | 12-17-2009 |
20100144825 | Renin Inhibitors - The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors. | 06-10-2010 |
20100168243 | Renin Inhibitors - The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors. | 07-01-2010 |
20100184805 | RENIN INHIBITORS - Disclosed are aspartic protease inhibitors represented by the following structural formula: and pharmaceutically acceptable salts thereof. These compounds are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. The present invention is also directed to pharmaceutical compositions comprising a compound described herein or enantiomers, diastereomers, or salts thereof and a pharmaceutically acceptable carrier or excipient. | 07-22-2010 |
20100190829 | RENIN INHIBITORS - Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof. | 07-29-2010 |
20110071126 | INHIBITORS OF BETA-SECRETASE - The present invention is directed to a compound represented by the following structural formula | 03-24-2011 |
20110098321 | SALTS OF METHYL 2-((R)-(3-CHLOROPHENYL)((R)-1-((S)-2-(METHYLAMINO)-3-((R)-TETRAHYDRO-2H-P- YRAN-3-YL)PROPYLCARBAMOYL)PIPERIDIN-3-YL)METHOXY)ETHYLCARBAMATE - Mucic acid salts of a compound represented by the following structural formula: | 04-28-2011 |
20110218192 | Inhibitors Of Beta-Secretase - The present invention is directed to a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof. Pharmaceutical composition comprising a compound represented by Structural Formula (I) and method of use of these compound for inhibiting BACE activity in a subject in need of such treatment are also described. | 09-08-2011 |
20120225906 | PIPERIDINE RENIN INHIBITORS - The present invention is directed to aspartic protease inhibitors represented by the following structural formula: | 09-06-2012 |
20130197034 | Salts Of Methyl 2-((R)-(3-Chlorophenyl)((R)-1-((S)-2-(Methylamino)-3-((R)-Tetrahydro-2H-P- yran-3-Yl)Propylcarbamoyl)Piperidin-3-Yl)Methoxy)Ethylcarbamate - Mucic acid salts of a compound represented by the following structural formula: | 08-01-2013 |
20130289050 | INHIBITORS OF BETA-SECRETASE - The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates. | 10-31-2013 |
20130317014 | INHIBITORS OF BETA-SECRETASE - The present invention is directed to a compound represented by the following structural formula: | 11-28-2013 |
20140057927 | INHIBITORS OF BETA-SECRETASE - The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates. | 02-27-2014 |
20140200223 | INHIBITORS OF BETA-SECRETASE - The present invention is directed to a compound represented by the following structural formula | 07-17-2014 |
20150031691 | INHIBITORS OF BETA-SECRETASE - The present invention relates to compounds represented by Structural Formula (I): | 01-29-2015 |